12/9
09:39 am
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
Low
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
12/9
08:00 am
coya
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
Low
Report
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
11/25
08:45 am
coya
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences [Yahoo! Finance]
Low
Report
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences [Yahoo! Finance]
11/25
08:00 am
coya
ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman
Low
Report
ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman
11/25
08:00 am
coya
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences
Low
Report
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences
11/24
07:02 am
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/15
01:42 am
coya
Coya Therapeutics (NASDAQ:COYA) was upgraded by analysts at
Wall Street
Medium
Report
Coya Therapeutics (NASDAQ:COYA) was upgraded by analysts at
Wall Street
11/14
08:26 am
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
Low
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
11/13
01:39 pm
coya
Coya Therapeutics (NASDAQ:COYA) had its price target raised by analysts at BTIG Research from $15.00 to $16.00. They now have a "buy" rating on the stock.
Low
Report
Coya Therapeutics (NASDAQ:COYA) had its price target raised by analysts at BTIG Research from $15.00 to $16.00. They now have a "buy" rating on the stock.
11/12
02:21 pm
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
Low
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
11/12
08:00 am
coya
Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
Low
Report
Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
11/5
11:02 am
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at Lake Street Capital.
Low
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at Lake Street Capital.
11/4
08:00 am
coya
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo
Medium
Report
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo
10/27
04:01 pm
coya
Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
Low
Report
Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
10/24
08:10 pm
coya
Coya Therapeutics (COYA) Valuation in Focus After Follow-On Equity Offering Announced [Yahoo! Finance]
Low
Report
Coya Therapeutics (COYA) Valuation in Focus After Follow-On Equity Offering Announced [Yahoo! Finance]
10/24
06:30 am
coya
Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock
Medium
Report
Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock
10/23
04:31 pm
coya
Coya Therapeutics Announces Proposed Public Offering of Common Stock
Medium
Report
Coya Therapeutics Announces Proposed Public Offering of Common Stock
10/8
02:23 pm
coya
Phantom Neuro CEO Connor Glass to Present during BioFuture™ 2025 [Yahoo! Finance]
Low
Report
Phantom Neuro CEO Connor Glass to Present during BioFuture™ 2025 [Yahoo! Finance]
10/7
08:22 am
coya
Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function [Yahoo! Finance]
Medium
Report
Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function [Yahoo! Finance]
10/7
08:00 am
coya
Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function
Medium
Report
Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function
9/30
08:05 am
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $15.00 price target on the stock.
Low
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $15.00 price target on the stock.
9/29
09:50 am
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $18.00 price target on the stock.
Low
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $18.00 price target on the stock.
9/29
08:21 am
coya
Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia [Yahoo! Finance]
Low
Report
Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia [Yahoo! Finance]
9/29
08:00 am
coya
Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia
Low
Report
Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia
9/22
08:15 am
coya
Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis [Yahoo! Finance]
Low
Report
Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis [Yahoo! Finance]